Literature DB >> 9359493

Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent.

S L Mooberry1, L Busquets, G Tien.   

Abstract

The ability of cryptophycin 1, a new potent cytotoxic antimicrotubule agent, to initiate apoptosis was studied. Treatment of cells with cryptophycin 1 (50 pM) rapidly caused morphological changes consistent with the induction of apoptosis. DNA strand breakage and fragmentation of the DNA into oligonucleosome-sized fragments was observed, and this coincided with the loss of cellular DNA. Activation of the cysteine protease CPP32 (caspase 3, YAMA, apopain), a member of the ICE/CED-3-like protease family of apoptosis effectors, was consistent with the execution of cell death by a coordinated sequence of events. Low concentrations of cryptophycin 1 caused mitotic arrest with the formation of abnormal mitotic spindles without affecting interphase microtubule structures. Unlike other microtubule active agents, cryptophycin-induced mitotic arrest persisted for only a brief period before the onset of apoptosis. There was no evidence of release from G2/M cell cycle arrest. Our results show that low concentrations of cryptophycin 1 (50 pM) initiated cell death consistent with apoptosis. These data suggest that the cytotoxic effects of cryptophycin 1 are due in part to its ability to initiate apoptosis rapidly.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359493     DOI: 10.1002/(sici)1097-0215(19971104)73:3<440::aid-ijc20>3.0.co;2-f

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.

Authors:  Jian Liang; Richard E Moore; Eric D Moher; John E Munroe; Rima S Al-awar; David A Hay; David L Varie; Tony Y Zhang; James A Aikins; Michael J Martinelli; Chuan Shih; James E Ray; Lowell L Gibson; Vasu Vasudevan; Lisa Polin; Kathryn White; Juiwanna Kushner; Chiab Simpson; Susan Pugh; Thomas H Corbett
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

Review 2.  Therapeutic potential of marine peptides in cervical and ovarian cancers.

Authors:  Salman Ahmed; Haroon Khan; Sajad Fakhri; Michael Aschner; Wai San Cheang
Journal:  Mol Cell Biochem       Date:  2021-12-02       Impact factor: 3.396

Review 3.  Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?

Authors:  Daniele Fanale; Giuseppe Bronte; Francesco Passiglia; Valentina Calò; Marta Castiglia; Florinda Di Piazza; Nadia Barraco; Antonina Cangemi; Maria Teresa Catarella; Lavinia Insalaco; Angela Listì; Rossella Maragliano; Daniela Massihnia; Alessandro Perez; Francesca Toia; Giuseppe Cicero; Viviana Bazan
Journal:  Anal Cell Pathol (Amst)       Date:  2015-09-21       Impact factor: 2.916

Review 4.  Recent Advances in Small Peptides of Marine Origin in Cancer Therapy.

Authors:  Qi-Ting Zhang; Ze-Dong Liu; Ze Wang; Tao Wang; Nan Wang; Ning Wang; Bin Zhang; Yu-Fen Zhao
Journal:  Mar Drugs       Date:  2021-02-19       Impact factor: 5.118

5.  Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development.

Authors:  A Kruczynski; C Etiévant; D Perrin; N Chansard; A Duflos; B T Hill
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

Review 6.  Marine cyanobacteria compounds with anticancer properties: a review on the implication of apoptosis.

Authors:  Margarida Costa; João Costa-Rodrigues; Maria Helena Fernandes; Piedade Barros; Vitor Vasconcelos; Rosário Martins
Journal:  Mar Drugs       Date:  2012-09-28       Impact factor: 6.085

Review 7.  Marine Cyanobacteria and Microalgae Metabolites-A Rich Source of Potential Anticancer Drugs.

Authors:  Arijit Mondal; Sankhadip Bose; Sabyasachi Banerjee; Jayanta Kumar Patra; Jai Malik; Sudip Kumar Mandal; Kaitlyn L Kilpatrick; Gitishree Das; Rout George Kerry; Carmela Fimognari; Anupam Bishayee
Journal:  Mar Drugs       Date:  2020-09-19       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.